Robert Davis, chief executive of Merck & Co Inc, has been appointed chairman of the board of directors, effective 1 December. He succeeds Kenneth Frazier, former CEO and chair, who is retiring after a career at Merck that began in 1992. Mr Davis joined Merck as chief financial officer in 2014 and became president in April 2021. He was named CEO and a member of the board in July of that year. Prior to joining Merck, Mr Davis was president of the medical products business of Baxter International Inc. He holds both juris doctor (JD) and MBA degrees respectively, from Northwestern University School of Law and the university’s Kellogg Graduate School of Management.
Merck announced the appointment on 26 October 2022
Copyright 2022 Evernow Publishing Ltd